Marta Wilejto, Staff Physician, Pediatric Hematology/Oncology, London Health Sciences Centre, shared a post on X:
“The future (and present) of ALL therapy is Blinatumomab .. this is very clear.
But innovative therapies are expensive. Our responsibility is to make blin available for all including LMIC.
How to do this remains a challenge.”
